Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China flag China · Delayed Price · Currency is CNY
5.03
-0.11 (-2.14%)
Nov 13, 2026, 3:04 PM CST

Beijing SL Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
544.49612.49652.741,0051,0331,199
Other Revenue
11.1511.157.6812.9817.0516.05
555.64623.64660.421,0181,0501,215
Revenue Growth
-3.97%-5.57%-35.15%-3.03%-13.55%9.17%
Cost of Revenue
226.18236.87212.09188.81156.96183.57
Gross Profit
329.46386.77448.33829.55893.211,031
Selling, General & Admin
233.73274.7259.91405.65546.76585.32
Research & Development
96.05115.4149.62177.11161.65196.15
Other Operating Expenses
6.350.381.662.899.211.22
Operating Expenses
339.18394.45420.68609.45749.55818.94
Operating Income
-9.72-7.6827.65220.1143.66212.3
Interest Expense
-----0.1-0.23
Interest & Investment Income
17.0318.0921.5248.4693.84112.26
Currency Exchange Gain (Loss)
0.190.19-0.90.70.020.05
Other Non Operating Income (Expenses)
-611.6-617.23-1.66-1.83-0.21-0.23
EBT Excluding Unusual Items
-604.1-606.6346.61267.44237.21324.14
Gain (Loss) on Sale of Investments
-231.38342.77-172.29205.2119.49113.58
Gain (Loss) on Sale of Assets
-0.05-0.0500.010.213.22
Asset Writedown
-15.64-15.64---0-0.02
Other Unusual Items
1.221.4-8.07-7.762.4516.91
Pretax Income
-849.95-278.14-133.75464.89259.35457.84
Income Tax Expense
-9.8770.06-58.4649.9431.0136.51
Earnings From Continuing Operations
-840.09-348.21-75.29414.96228.34421.33
Minority Interest in Earnings
1.661.011.221.736.064.61
Net Income
-838.43-347.2-74.07416.69234.4425.94
Net Income to Common
-838.43-347.2-74.07416.69234.4425.94
Net Income Growth
---77.77%-44.97%16.79%
Shares Outstanding (Basic)
1,0211,0211,0581,0161,0191,039
Shares Outstanding (Diluted)
1,0211,0211,0581,0161,0191,039
Shares Change
-3.57%-3.49%4.11%-0.28%-1.90%2.55%
EPS (Basic)
-0.82-0.34-0.070.410.230.41
EPS (Diluted)
-0.82-0.34-0.070.410.230.41
EPS Growth
---78.26%-43.90%13.89%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
497.7964.69-121.89241.84226.33227.72
Free Cash Flow Per Share
0.490.06-0.120.240.220.22
Dividend Per Share
0.0100.0100.0200.1500.1000.100
Dividend Growth
-50.00%-50.00%-86.67%50.00%0%0%
Gross Margin
59.29%62.02%67.89%81.46%85.05%84.89%
Operating Margin
-1.75%-1.23%4.19%21.61%13.68%17.48%
Profit Margin
-150.89%-55.67%-11.21%40.92%22.32%35.06%
Free Cash Flow Margin
89.59%10.37%-18.46%23.75%21.55%18.75%
EBITDA
167.41159.09180.6365.5257.17311.97
EBITDA Margin
30.13%25.51%27.35%35.89%24.49%25.68%
D&A For EBITDA
177.13166.77152.96145.4113.5199.67
EBIT
-9.72-7.6827.65220.1143.66212.3
EBIT Margin
-1.75%-1.23%4.19%21.61%13.68%17.48%
Effective Tax Rate
---10.74%11.96%7.98%
Revenue as Reported
164.89623.64660.421,0181,0501,215